Abstract
Telbivudine (Tyzeka; Idenix/Novartis), a nucleoside analogue that inhibits the hepatitis B virus polymerase, was approved by the US FDA in October 2006 for the treatment of adults with chronic hepatitis B.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
BMC Infectious Diseases Open Access 12 July 2019
-
Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
BMC Gastroenterology Open Access 13 April 2017
-
The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
Virology Journal Open Access 04 September 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lee, W. M. Hepatitis B virus infection N. Engl. J. Med. 337, 1733–1745 (1997).
Jacobson, I. M. Therapeutic options for chronic hepatitis B: considerations and controversies. Am. J. Gastroenterol. 101 (Suppl. 1), 13–17 (2005).
Dienstag, J. L. Looking to the future: new agents for chronic hepatitis B. Am. J. Gastroenterol. 101 (Suppl. 1), 19–25 (2005).
Lai, C. L. et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687–696 (2003).
Bryant, M. L. et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45, 229–235 (2001).
Hernandez-Santiago B. et al. Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46, 1728–1733 (2002).
Food and Drug Administration. FDA labelling information [online], (2006).
Lai, C. L. et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international Phase III GLOBE trial. Hepatology 42 (Suppl 1), 748A (2005).
Lai, C. L. et al. Results of a one-year international Phase IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 38 (Suppl 1), 262A (2003).
Chang, T. T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001–1010 (2006).
Lai, C. L. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011–1020 (2006).
Chang, T. T. et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901). Hepatology 44 (Suppl 1), 229A (2006).
Lai, C. L. et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 44 (Suppl 1), 222A (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Jules Dienstag has served on or serves on advisory boards for the following companies: GlaxoSmithKline, Vertex, Bristol-Myers Squibb,Gilead Sciences, Idenix, Achillion, Metabasis, SciClone, Nucleonics, Valeant, Wyeth and AstraZeneca. He has acted or is acting as a consultant for Oxxon Therapeutics, CombinatoRx, Pharmasset and Biogen-Idec. In addition, he has been involved with or is involved with committees for Gilead, Schering-Plough Research Institute and Genzyme. He has received research support from Vertex.
Rights and permissions
About this article
Cite this article
Dienstag, J., Easley, C. & Kirkpatrick, P. Telbivudine. Nat Rev Drug Discov 6, 267–268 (2007). https://doi.org/10.1038/nrd2295
Issue Date:
DOI: https://doi.org/10.1038/nrd2295
This article is cited by
-
Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
BMC Infectious Diseases (2019)
-
Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
BMC Gastroenterology (2017)
-
The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
Virology Journal (2012)